Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and ...
[5] McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024 Jan;23(1):47-55. doi: 10.1080...
2021年12月20日,来自德国Integrated Drug Discovery的Martin Bossart团队和德国TA Diabetes的Anish Konkar团队在Cell Metabolism杂志上合作发表了一篇题为Effects on weight loss and glycemic control with SAR441255, a potent unimolecul...
GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme
[9] Zhang, Xiaolong, et al. "Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists." Peptides 161 (2023): 170948.[10] Liu, Chunxia, Yuxing Zou, and Hai Qian. "GLP-1R agonists for the treatment of obesity: a patent review (2015-present)." ...
药物靶点作用机制在研适应症药物最高研发状态(全球)药物类型在研机构GMA102/105(重组抗人GLP-1受体人源化单克隆抗体)GIP-1RGIP-1R激动剂2型糖尿病;肥胖;超重临床3期单克隆抗体鸿运华宁(杭州)生物医药有限公司(Gmax Biopharm LLC)Recombinant GLP-1 receptor agonists (Beijing Lepu)(重组GLP-1受体激动剂GIP-1RG...
[7] Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J., Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A system...
GLP-1具有葡萄糖浓度依赖性降糖作用,其受体激动剂(GLP-1RA)能模拟GLP-1的生理作用,是治疗糖尿病与肥胖症的重要药物。此外,GLP-1RA亦对心血管系统、肾脏、中枢神经系统等有保护作用。 来源:Anti-obesity drug discovery: advances and challenges.Nature Reviews....
GLP-1具有葡萄糖浓度依赖性降糖作用,其受体激动剂(GLP-1RA)能模拟GLP-1的生理作用,是治疗糖尿病与肥胖症的重要药物。此外,GLP-1RA亦对心血管系统、肾脏、中枢神经系统等有保护作用。 来源:Anti-obesity drug discovery: advances and challenges.Nature Reviews....
GLUCAGON-like peptide-1 agonistsGLUCAGON-like peptide-1 receptorDOPAMINE receptorsCOGNITIVE abilityThe global burden of chronic disorders such as Parkinson's disease (PD) has rapidly increased over recent decades. Despite an increasing understanding of PD pathophysiology, there are no effective therapies ...